Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 134
Selected: 0
NCT IDTitle
NCT05827926A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT03829384Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
NCT05831787COVID19 OutcomeS in Myeloma and the Impact of VaCcines
NCT04956575A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
NCT05566639A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT05894590Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
NCT03392389Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
NCT04860297A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
NCT04899310A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
NCT07279766Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
NCT05769621A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT06655870A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
NCT05831111A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
NCT05933304A Study of the Effectiveness of Moderna COVID-19 Vaccine
NCT06295809A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
NCT05249829A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
NCT06333704Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.
NCT06602024A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06133010A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
NCT03897881An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT05295433An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
NCT04159103Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT06033261A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
NCT04958304Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
NCT04405076Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
NCT05995275A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
NCT03739931Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
NCT06060457A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
NCT05972174A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults
NCT05575492A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT03484767"The MaP Study": Mapping the Patient Journey in MMA and PA
NCT05164094A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT06147856A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
NCT06189053A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
NCT03382405Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
NCT04805125Immunocompromised Swiss Cohorts Based Trial Platform
NCT03325075Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
NCT04958954Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
NCT06097299A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
NCT05827068A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults
NCT05367908A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
NCT05572658Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
NCT07221474A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT05584202Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT03313778Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT05894499Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
NCT06694753Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.
NCT05918250mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT02872025Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)